Forecast Period 
Market Size (Base Year) 
Market Size (Forecast Year)
CAGRGlobal Eosinophilic Esophagitis Market, By product (Budesonide Oral Suspension, Fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab and Others), By diagnosis (Upper Endoscopy, Esophagus Biopsy and Blood Tests, By treatment (Dietary Therapy, Medication and Dilation)-Industry Trends and Forecast to 2029
Market Analysis and Size
Eosinophilic esophagitis growth is due to the occurrence of a deficient mucosal obstruction in the esophagus and reverse immune reaction producing fissures/lesions, fibrosis, and dysmotility in the esophagus, facilitated by Th2 interleukins. Eosinophilic esophagitis is multi-factorial, with around a 7 percent risk of genetic inheritance. Food dislikes, and exposure to unnecessary use of antibiotics, acid conquest, and early life indications of gastro-intestinal illnesses are also predominant market factors.
Data Bridge Market Research analyses that the eosinophilic esophagitis market which was USD 138.4 million in 2021, would rocket up to USD 1379.68% million by 2029, and is expected to undergo a CAGR of 33.3% during the forecast period of 2022 to 2029. This indicates that the market value. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Eosinophilic Esophagitis (EoE) is definite as a chronic, immune-mediated, atopic inflammatory condition of the esophagus, predictable over the past two decades. EoE's eosinophils infiltrate the esophagus, causative to tissue mutilation and chronic tenderness. It is analysed by histologic analysis of ≥15 eosinophils per high influence field (eos/hpf) in one or more esophageal biopsy specimens and prohibiting of pathologic gastrointestinal reflux ailment (GERD).
Report Scope and Market Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (On Casters, Wall Mounted, Table Top, Ceiling Mounted), Price Range (Low-Range, Mid-Range, Premium-Range), Application (Neuro and Spine Surgery, Plastic and Reconstructive Surgery, Ophthalmology, Gynecology and Urology, Oncology, Ear, Nose, and Throat (ENT) Surgery, Dentistry, Documentation), End User (Hospitals, Outpatient Facilities, Ambulatory Centers, Clinics, Others) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
GlaxoSmithKline(England), Regeneron Pharmaceuticals (New York), Allakos Inc(West Coast), Arena Pharmaceuticals(California), Revolo Biotherapeutics (US), DBV Technologies(France), Landos Biopharma(USA), Cipla Limited(India), Sun Pharmaceutical Industries Limited(Mumbai), AstraZeneca Plc(London), Sanofi S.A.( France), Arena Pharmaceuticals, Inc.( California) and others. |
|
Market Opportunities |
|
Eosinophilic Esophagitis Market Dynamics
Drivers
- Increasing awareness programs for Eosinophil-associated disorders
Numerous awareness plans have been advanced and implemented to educate the public and medical community about eosinophil-associated complaints which is anticipated to drive the market growth over the forecast period. The American Enterprise for Eosinophilic Disorders (APFED), a non-profit organization, was created in December 2001, which works on educating, hovering consciousness, supporting, and advocating for patients and families who are suffering from eosinophil-associated ailments.
- Sales of high-priced biologics
It represents the greatest impactful driver of growth for the EoE market. The introduction of Dupixent (dupilumab) for pediatrics, youngsters, and adults is expected to upsurge the sales significantly. Also, low diagnosis rates caused by imperfect illness awareness will endure to save the analyzed cases at a low rate.
Opportunities
Still, increase in the public-private subsidy for target investigation activities, rising demand for minimally invasive surgeries, growing sharing of youngsters in sports and rising product inventions and development due to technological progressions all everywhere the world will extend profitable cases for the market players in the forecast period of 2022 to 2029. Additionally, increasing internet diffusion rate, cumulative implementation of arthroscopic surgeries, growth in the old and obese populace internationally and growing per capita spending on health care will auxiliary expand the market's growth rate in the future.
Restraints/Challenges
- Stringent Regulations for Drug Approval
As of nowadays, no exact action has been accepted for eosinophilic esophagitis in the U.S. Marketplace players are focusing on early drug applicants for the treatment of EoE. However, many tasks are associated with obtaining approval from the regulatory authorities, which is probable to delay the market growth over the forecast period.
This eosinophilic esophagitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the eosinophilic esophagitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Eosinophilic Esophagitis Market
The coronavirus (COVID-19) pandemic was first described on December 31, 2019 in Wuhan, China. The World Health Organization (WHO) declared the COVID-19 a pandemic on March 11, 2020. A number of research have been carried out to depict the relative between the COVID-19 and eosinophilic esophagitis (EoE). Additionally, research has been ongoing in which academics are discovery the association of transience in patients due to the COVID-19 and eosinophilic esophagitis.
Recent Development
- Moreover, in August 2019, AstraZeneca publicized that FDA has approved orphan medicine title to its drug candidate Fasenra (benralizumab), used in the action of EoE. FDA grants this place to drug candidates which are future to avert rare disorders/diseases, affecting less than 200,000 individuals in the U.S. market.
- In September 2020, Sanofi’s medication contender Dupixent (dupilumab) reputable advance therapy description from the U.S. Food and Drug Administration (FDA) to treat eosinophilic esophagitis patients of 12 years and older in alliance with Regeneron.
Global Eosinophilic Esophagitis Market Scope
The eosinophilic esophagitis market is segmented on the basis of type, price range, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
By Product
- Budesonide Oral Suspension
- Fluticasone ODT
- Mepolizumab
- Reslizumab
- Benralizumab
- Others
On the basis of product the market is segmented into Budesonide Oral Suspension, Fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab and Others.
By Diagnosis
- Upper Endoscopy
- Esophagus Biopsy
- Blood Tests
On the basis of product the market is segmented into Upper Endoscopy, Esophagus Biopsy and Blood Tests.
By Treatment
- Dietary Therapy
- Medication
- Dilation
On the basis of product the market is segmented into Dietary Therapy, Medication and Dilation.
Eosinophilic Esophagitis Market Regional Analysis/Insights
The eosinophilic esophagitis market is analysed and market size insights and trends are provided by country, type, price range, application and end user as referenced above.
The countries covered in the eosinophilic esophagitis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the eosinophilic esophagitis market because of the strong base of healthcare facilities, strong attendance of major players in the market, increases cases of surgical procedures among the athletes and rising number of research actions in this region.
Asia-Pacific is expected to witness important growth during the forecast period of 2022 to 2029 due to the rise in government creativities to promote awareness, growing in medical tourism, growing investigation activities in the region, availability of massive unexploited markets, large population pool, and the upward claim for superiority healthcare in the province.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The eosinophilic esophagitis market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Eosinophilic Esophagitis market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the eosinophilic esophagitis market. The data is available for historic period 2010-2020.
Competitive Landscape and Eosinophilic Esophagitis Market Share Analysis
The eosinophilic esophagitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to eosinophilic esophagitis market.
Some of the major players operating in the eosinophilic esophagitis market are:
- Takeda Pharmaceuticals(Osaka)
- Ellodi Pharmaceuticals(NJ)
- Bristol Myers Squibb(US)
- AstraZeneca(London)
- GlaxoSmithKline(England)
- Regeneron Pharmaceuticals (New York)
- Allakos Inc(West Coast)
- Arena Pharmaceuticals(California)
- Revolo Biotherapeutics (US)
- DBV Technologies(France)
- Landos Biopharma(USA)
- Cipla Limited(India)
- Sun Pharmaceutical Industries Limited(Mumbai)
- AstraZeneca Plc(London)
- Sanofi S.A.( France)
- Arena Pharmaceuticals, Inc.( California)
- Takeda Pharmaceutical Company Limited(Japan)
- Revolo Biotherapeutics( US)
- Bristol-Myers Squibb Co(New York)
- Calypso Biotech (Switzerland)
- DBV Technologies (France)
- Landos Biopharma, Inc.( Southern US)
- Glenmark Pharmaceuticals(NJ)
SKU-
